Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Sets Collaboration With Nurix Therapeutics

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/19/2019 | 09:05am EDT

By Colin Kellaher

Gilead Sciences Inc. (GILD) on Wednesday said it would collaborate with privately held biotechnology company Nurix Therapeutics Inc. to develop new therapies for cancer and other diseases.

Gilead said it will make an upfront payment of $45 million to Nurix, which is working to discover drugs that harness the body's natural process to control protein levels.

San Francisco-based Nurix will also be eligible for up to roughly $2.3 billion in additional milestone payments, along with royalties on product sales, Gilead said.

The Foster City, Calif., biopharmaceutical company said it will have an option to license drug candidates directed to up to five targets resulting from its work with Nurix, which is backed by life-science investors Third Rock Ventures and Column Group.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
07/19GILEAD SCIENCES : Murad Ali Shah says his government working hard to contain spr..
AQ
07/19SINDH GOVT ALLOCATES RS 600M TO CONT : CM Sindh
AQ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19GILEAD SCIENCES : Licenses Respiratory and Herpes Antiviral Research Programs Fr..
BU
07/19GILEAD SCIENCES : Sindh govt allocates Rs600m to contain HIV, says Murad
AQ
07/18GILEAD SCIENCES INC : Entry into a Material Definitive Agreement, Financial Stat..
AQ
07/18GILEAD SCIENCES : to Present New Data on HIV Prevention, Treatment and Cure Rese..
BU
07/18GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave the Company
AQ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/17GILEAD SCIENCES INC : Change in Directors or Principal Officers, Financial State..
AQ
More news
Financials (USD)
Sales 2019 22 022 M
EBIT 2019 11 470 M
Net income 2019 7 013 M
Debt 2019 2 514 M
Yield 2019 3,87%
P/E ratio 2019 11,9x
P/E ratio 2020 11,8x
EV / Sales2019 3,87x
EV / Sales2020 3,54x
Capitalization 82 702 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,65  $
Last Close Price 65,04  $
Spread / Highest target 46,1%
Spread / Average Target 24,0%
Spread / Lowest Target -9,29%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES3.98%82 702
VERTEX PHARMACEUTICALS5.08%44 598
REGENERON PHARMACEUTICALS-20.18%32 544
GENMAB14.24%11 908
SAREPTA THERAPEUTICS INC36.77%11 068
ARRAY BIOPHARMA INC226.25%10 372